Department of Biochemistry, Faculty of Medicine of Sousse, Sousse, Tunisia.
Eur Neurol. 2009;62(6):349-55. doi: 10.1159/000241881. Epub 2009 Sep 26.
Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. Cerebrospinal fluid (CSF) concentrations of amyloid beta (Abeta1-42) peptides and total tau proteins (T-tau) may serve as biomarkers for AD.
The objective of this study was to investigate the usefulness of CSF Abeta1-42 and T-tau analyses in the diagnosis of AD with Tunisians.
We focused on three groups originating from Central Tunisian that matched in age (range 48-85): healthy controls (n = 53), AD patients (n = 93) and non-Alzheimer (nAD) dementia (n = 35) patients. Abeta1-42 and T-tau levels were measured in CSF by sandwich enzyme-linked immunosorbent assay.
The ratio of T-tau/Abeta1-42 at baseline yielded a sensitivity of 85.3% for detection of AD and the specificity was 84.8% to differentiate controls and nAD dementia.
Our findings confirm the use of T-tau/Abeta1-42 ratio in the discrimination of AD patients from all other patients.
阿尔茨海默病（AD）是痴呆症的主要病因。目前，尚无针对 AD 的明确诊断测试。脑脊液（CSF）中淀粉样蛋白β（Abeta1-42）肽和总tau 蛋白（T-tau）的浓度可作为 AD 的生物标志物。
本研究旨在探讨 CSF Abeta1-42 和 T-tau 分析在突尼斯人 AD 诊断中的作用。
我们专注于三个来自突尼斯中部的年龄匹配的组（48-85 岁）：健康对照组（n=53）、AD 患者组（n=93）和非阿尔茨海默病（nAD）痴呆症患者组（n=35）。通过夹心酶联免疫吸附测定法测量 CSF 中 Abeta1-42 和 T-tau 水平。
基线时 T-tau/Abeta1-42 比值对 AD 的检测具有 85.3%的敏感性，特异性为 84.8%，可区分对照组和 nAD 痴呆症患者。
我们的研究结果证实了 T-tau/Abeta1-42 比值在区分 AD 患者与所有其他患者中的作用。
